MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Abeona Therapeutics Inc. (NASDAQ: ABEO)*
Organization & Developments: Abeona
Parents
Abeona Therapeutics Inc. (NASDAQ: ABEO)*
Children
2017: Abeona Therapeutics: Transitioning To Late-Stage Studies - Abeona Therapeutics Inc. (NASDAQ:ABEO)
2017: Abeona's EB-101 a Breakthrough Therapy in U.S. for rare skin-blistering disorder; shares ahead 8% - Abeona Therapeutics Inc. (NASDAQ:ABEO)
2017: Relieving Suffering From Genetic Disease - Abeona Therapeutics - Abeona Therapeutics Inc. (NASDAQ:ABEO)
2018 Could Be Another Solid Year For Abeona Therapeutics - Abeona Therapeutics Inc. (NASDAQ:ABEO)
2018: Abeona Therapeutics: Continued Upside In 2018 - Abeona Therapeutics Inc. (NASDAQ:ABEO)
2018: Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results - Abeona Therapeutics Inc. (NASDAQ:ABEO)
2019: Abeona Therapeutics: A True Test Looms As Cash Dwindles_seekingalpha.com
2019: Abeona Therapeutics: Speculative Buy After Financing_seekingalpha.com
2021: The Right Play On Abeona Therapeutics
2022: Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value_seekingalpha.com
2024: Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy
2024: Another delay for Abeona's topical gene therapy pz-cel as FDA sends out a rejection
2025: Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued_seekingalpha.com
2025:Is Abeona Therapeutics' Zevaskyn Worth $3.1m Per Treatment, Or Will Krystal Biotech Remain The Market Leader?
Jumps
*Key People: Abeona
Finance & Acquisitions: Abeona